

WHAT IS CLAIMED IS:

1. Use of an anti-IL-23 antibody in the manufacture of a medicament for treating ulcerative colitis in a subject, wherein a therapeutically effective amount of the anti-IL-23 antibody that does not inhibit IL-12 is to be administered to the subject, and wherein the anti-IL-23 antibody comprises the CDRH1 of SEQ ID NO:3, the CDRH2 of SEQ ID NO:4, the CDRH3 of SEQ ID NO:5, the CDRL1 of SEQ ID NO:6, the CDRL2 of SEQ ID NO:7 and the CDRL3 of SEQ ID NO:8.
2. The use of claim 1 wherein the subject has moderately to severely active ulcerative colitis as determined by a colonoscopy.
3. The use of claim 1 wherein the anti-IL-23 antibody is to be administered as a plurality of intravenous infusions during an induction period.
4. The use of claim 3 wherein a total dosage of at least 720 mg or at least 1440 mg of anti-IL-23 antibody is to be administered during each intravenous infusion.
5. The use of claim 3 wherein a total dosage of at least 720 mg of the anti-IL-23 antibody is to be administered during each intravenous infusion.
6. The use of claim 3 wherein a total dosage of at least 1440 mg of the anti-IL-23 antibody is to be administered during each intravenous infusion.
7. The use of claim 4 wherein the plurality of intravenous infusions administered during the induction period comprises three intravenous infusions.
8. The use of claim 7 wherein the plurality of intravenous infusions each comprises the same quantity of anti-IL-23 antibody.
9. The use of claim 4 wherein the anti-IL-23 antibody is to be administered subcutaneously as a plurality of doses during a maintenance period following the induction period.
10. The use of claim 9 wherein a total dosage of at least 240 mg of anti-IL-23 antibody is to be administered subcutaneously every four weeks during the maintenance period.
11. The use of claim 9 wherein a total dosage of at least 240 mg of the anti-IL-23 antibody is to be administered subcutaneously every eight weeks during the maintenance period.
12. The use of claim 1 further comprising measuring the effect of the therapy using the modified Mayo Score/Disease Activity Index for Ulcerative Colitis.

13. The use of claim 12 wherein the therapy lowers the score of at least two components of the modified Mayo Score/Disease Activity Index for Ulcerative Colitis, wherein the components are selected from the group consisting of Stool Frequency, Rectal Bleeding, Endoscopy Findings and Physicians' Global Assessment.

14. The use of claim 1 wherein the anti-IL-23 antibody comprises the heavy chain variable region sequence of SEQ ID NO:1.

15. The use of claim 1 wherein the anti-IL-23 antibody comprises the light chain variable region sequence of SEQ ID NO:2.

16. The use of claim 1 wherein the anti-IL-23 antibody comprises the heavy chain variable region sequence of SEQ ID NO:1 and the light chain variable region sequence of SEQ ID NO:2.